Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

AUTL Autolus Therapeutics PLC

4,19

0,00 (0,00%)

Vor Marktöffnung

Zuletzt aktualisiert: 10:01:04

Verzögert um 15 Minuten

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

null

Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Click Here for more Autolus Therapeutics Charts.

Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
Von Jun 2023 bis Jun 2024

Click Here for more Autolus Therapeutics Charts.

News Autolus Therapeutics PLC

Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO
Freitag 31 Mai 2024 (3 Tage vor) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Freitag 17 Mai 2024 (2 Wochen vor) • Edgar (US Regulatory)

Form 8-K - Current report
Freitag 17 Mai 2024 (2 Wochen vor) • Edgar (US Regulatory)

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
Freitag 17 Mai 2024 (2 Wochen vor) • GlobeNewswire Inc.

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
Dienstag 14 Mai 2024 (3 Wochen vor) • GlobeNewswire Inc.

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB
Montag 13 Mai 2024 (3 Wochen vor) • Edgar (US Regulatory)

Form 8-K - Current report
Montag 13 Mai 2024 (3 Wochen vor) • Edgar (US Regulatory)

Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call
Montag 13 Mai 2024 (3 Wochen vor) • GlobeNewswire Inc.

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
Mittwoch 24 April 2024 (1 Monat vor) • GlobeNewswire Inc.

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
Dienstag 23 April 2024 (1 Monat vor) • GlobeNewswire Inc.

Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL
Dienstag 2 April 2024 (2 Monate vor) • GlobeNewswire Inc.

Autolus Therapeutics Announces Changes to its Board of Directors
Montag 1 April 2024 (2 Monate vor) • GlobeNewswire Inc.

Weitere Autolus Therapeutics PLC News-Artikel

Ishr E Gv 7-10a

LS 1x Facebook Tracker ETP

Investec Bnk 26

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen